^
Association details:
| Biomarker: | STAG3 underexpression |
|---|---|
| Cancer: | Melanoma |
| Drug: | Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma
Excerpt:
Similar to STAG2, knockdown of STAG3 in BRAF mutant melanoma cells also resulted in decreased sensitivities to dabrafenib or vemurafenib with regard to cell viability and ERK inhibition (Fig. 2g,h and Supplementary Fig. 4a–d)
DOI:
10.1038/nm.4155
